Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin + Empagliflozin + Linagliptin for type 2 diabetes with metabolic fatty liver
IRCT20120215009014N603Phase 3Completed
- Sponsor
- Hamadan University of Medical Sciences
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of metformin, empagliflozin and linagliptin in type 2 diabetes mellitus (T2DM) and metabolic dysfunction-associated steatotic liver disease (MASLD), sponsored by Hamadan University of Medical Sciences. Primary endpoint: Change in laboratory markers related to liver and metabolic function. Started Apr 2026; status: completed.
02
Drugs
metforminempagliflozinlinagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)metabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on IRCT20120215009014N603.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20120215009014N603.